Relevance,RGD ID,Symbol,Name,LOD,P Value,Trait,Sub Trait,Chr,Start,Stop,Species,Annotations,Match,Type 1000,2317035,Aia16,Adjuvant induced arthritis QTL 16,2.71,,joint integrity trait (VT:0010548),right rear ankle joint diameter (CMO:0002150),7,59238038,104238038,Rat,n/a,region,qtl 1000,2317052,Aia17,Adjuvant induced arthritis QTL 17,2.13,,joint integrity trait (VT:0010548),left rear ankle joint diameter (CMO:0002149),7,81737938,126737938,Rat,n/a,region,qtl 1000,634336,Anxrr17,Anxiety related response QTL 17,3.66,,locomotor behavior trait (VT:0001392),number of entries into a discrete space in an experimental apparatus (CMO:0000960),7,924703,115097879,Rat,n/a,region,qtl 1000,738030,Anxrr8,Anxiety related response QTL 8,4.1,,exploratory behavior trait (VT:0010471),number of entries into a discrete space in an experimental apparatus (CMO:0000960),7,46590070,91590070,Rat,n/a,region,qtl 1000,2293685,Bmd21,Bone mineral density QTL 21,4.2,0.0003,femur mineral mass (VT:0010011),total volumetric bone mineral density (CMO:0001728),7,47651439,92651439,Rat,n/a,region,qtl 1000,2293644,Bmd29,Bone mineral density QTL 29,5.4,0.0001,femur size trait (VT:1000369),femoral neck cross-sectional area (CMO:0001697),7,47651439,92651439,Rat,n/a,region,qtl 1000,2293696,Bmd32,Bone mineral density QTL 32,5.1,0.0001,femur strength trait (VT:0010010),femoral neck polar moment of inertia (CMO:0001670),7,47651439,92651439,Rat,n/a,region,qtl 1000,2300178,Bmd54,Bone mineral density QTL 54,5.3,0.0001,femur mineral mass (VT:0010011),volumetric bone mineral density (CMO:0001553),7,47651439,92651439,Rat,n/a,region,qtl 1000,1298528,Bp169,Blood pressure QTL 169,,0.0001,arterial blood pressure trait (VT:2000000),systolic blood pressure (CMO:0000004),7,61074194,106074194,Rat,n/a,region,qtl 1000,1300151,Bp181,Blood pressure QTL 181,3.36,,arterial blood pressure trait (VT:2000000),diastolic blood pressure (CMO:0000005),7,53612714,103945643,Rat,n/a,region,qtl 1000,1300132,Bp182,Blood pressure QTL 182,3.49,,arterial blood pressure trait (VT:2000000),blood pressure time series experimental set point of the baroreceptor response (CMO:0002593),7,19654317,84928080,Rat,n/a,region,qtl 1000,1331728,Bp214,Blood pressure QTL 214,2.825,,arterial blood pressure trait (VT:2000000),mean arterial blood pressure (CMO:0000009),7,80221299,124373579,Rat,n/a,region,qtl 1000,61357,Bp38,Blood pressure QTL 38,1.6,0.052,arterial blood pressure trait (VT:2000000),systolic blood pressure (CMO:0000004),7,41333674,119109060,Rat,n/a,region,qtl 1000,2293678,Bss24,Bone structure and strength QTL 24,6.71,0.0001,femur morphology trait (VT:0000559),femur cross-sectional area (CMO:0001661),7,47651439,92651439,Rat,n/a,region,qtl 1000,2293707,Bss32,Bone structure and strength QTL 32,7.64,0.0001,femur strength trait (VT:0010010),femur midshaft polar moment of inertia (CMO:0001669),7,47651439,92651439,Rat,n/a,region,qtl 1000,2293667,Bss42,Bone structure and strength QTL 42,7.25,0.0001,lumbar vertebra size trait (VT:0010518),lumbar vertebra cross-sectional area (CMO:0001689),7,47651439,92651439,Rat,n/a,region,qtl 1000,631540,Bw9,Body weight QTL 9,4.5,,body mass (VT:0001259),body weight (CMO:0000012),7,69736226,117455174,Rat,n/a,region,qtl 1000,631504,Cm27,Cardiac mass QTL 27,3.45,,heart left ventricle mass (VT:0007031),heart left ventricle wet weight (CMO:0000071),7,44421311,118198041,Rat,n/a,region,qtl 1000,1300149,Cm6,Cardiac mass QTL 6,4.09,,heart mass (VT:0007028),heart left ventricle weight to body weight ratio (CMO:0000530),7,43747099,102228765,Rat,n/a,region,qtl 1000,1559283,Emca4,Estrogen-induced mammary cancer QTL 4,3.7,,mammary gland integrity trait (VT:0010552),percentage of study population developing mammary tumors during a period of time (CMO:0000948),7,62004452,101773158,Rat,n/a,region,qtl 1000,1576303,Ept7,Estrogen-induced pituitary tumorigenesis QTL 7,3.7,,pituitary gland mass (VT:0010496),pituitary gland wet weight (CMO:0000853),7,62004452,101773158,Rat,n/a,region,qtl 1000,7411607,Foco15,Food consumption QTL 15,,0.001,eating behavior trait (VT:0001431),feed conversion ratio (CMO:0001312),7,75918751,120918751,Rat,n/a,region,qtl 1000,7411654,Foco25,Food consumption QTL 25,9.3,0.001,eating behavior trait (VT:0001431),feed conversion ratio (CMO:0001312),7,75918751,120918751,Rat,n/a,region,qtl 1000,634326,Hc3,Hypercalciuria QTL 3,2.1,,urine calcium amount (VT:0002985),urine calcium excretion rate (CMO:0000763),7,42787314,87787314,Rat,n/a,region,qtl 1000,1331768,Kidm10,Kidney mass QTL 10,4.62096,,kidney mass (VT:0002707),left kidney wet weight (CMO:0000083),7,80221299,125221299,Rat,n/a,region,qtl 1000,1300179,Kidm5,Kidney mass QTL 5,3.51,,kidney mass (VT:0002707),left kidney wet weight (CMO:0000083),7,43747012,135012528,Rat,n/a,region,qtl 1000,1331746,Kidm9,Kidney mass QTL 9,3.934,,kidney mass (VT:0002707),right kidney wet weight (CMO:0000082),7,80221299,112308525,Rat,n/a,region,qtl 1000,70173,Niddm19,Non-insulin dependent diabetes mellitus QTL 19,4.33,0.00005,blood glucose amount (VT:0000188),blood glucose level area under curve (AUC) (CMO:0000350),7,64002457,135012528,Rat,n/a,region,qtl 1000,724537,Niddm52,Non-insulin dependent diabetes mellitus QTL 52,,0.02,blood glucose amount (VT:0000188),blood glucose level area under curve (AUC) (CMO:0000350),7,80221299,93595843,Rat,n/a,region,qtl 1000,1643004,Pain2,Pain QTL 2,1,,mechanical nociception trait (VT:0002734),self mutilation severity score (CMO:0002145),7,9462246,98011544,Rat,n/a,region,qtl 1000,634331,Pia17,Pristane induced arthritis QTL 17,4.7,,joint integrity trait (VT:0010548),arthritic paw count (CMO:0001460),7,73829340,130221005,Rat,n/a,region,qtl 1000,2316952,Pur22,Proteinuria QTL 22,5.2,,urine protein amount (VT:0005160),urine protein level (CMO:0000591),7,68938720,113886318,Rat,n/a,region,qtl 1000,2316947,Rf58,Renal function QTL 58,7.8,,kidney glomerulus morphology trait (VT:0005325),index of glomerular damage (CMO:0001135),7,68938720,113886318,Rat,n/a,region,qtl 1000,61428,Scl3,Serum cholesterol level QTL 3,3.2,,blood cholesterol amount (VT:0000180),serum total cholesterol level (CMO:0000363),7,44867533,89867533,Rat,n/a,region,qtl 1000,631513,Scl7,Serum cholesterol level QTL 7,4.1,,blood cholesterol amount (VT:0000180),serum total cholesterol level (CMO:0000363),7,37960569,82960569,Rat,n/a,region,qtl 1000,10053722,Scort27,Serum corticosterone level QTL 27,2.41,0.0083,blood corticosterone amount (VT:0005345),plasma corticosterone level (CMO:0001173),7,43228750,88228750,Rat,n/a,region,qtl 1000,1358361,Sradr5,Stress Responsive Adrenal Weight QTL 5,5.55,,adrenal gland mass (VT:0010420),both adrenal glands wet weight (CMO:0000164),7,43747012,108555253,Rat,n/a,region,qtl 1000,1300127,Srn1,Serum renin concentration QTL 1,3.87,,blood renin amount (VT:0003349),plasma renin activity level (CMO:0000116),7,29409683,84928080,Rat,n/a,region,qtl 1000,1357338,Stl17,Serum triglyceride level QTL 17,3.23,,blood triglyceride amount (VT:0002644),serum triglyceride level (CMO:0000360),7,69736356,112729554,Rat,n/a,region,qtl 1000,2316955,Stl24,Serum triglyceride level QTL 24,7.1,,blood triglyceride amount (VT:0002644),plasma triglyceride level (CMO:0000548),7,68938720,113886318,Rat,n/a,region,qtl 1000,1641908,Teswt1,Testicular weight QTL 1,3.28,,testis mass (VT:1000644),both testes wet weight (CMO:0000175),7,80221299,94811326,Rat,n/a,region,qtl 1000,631529,Tls2,T-lymphoma susceptibility QTL 2,0,0.001,thymus integrity trait (VT:0010555),percentage of study population developing T-cell lymphomas during a period of time (CMO:0001911),7,80221299,109401111,Rat,n/a,region,qtl